During the first quarter 2020 earnings release, AMN Healthcare Services, Inc. (NYSE: AMN) announced an update to our reportable segments. Effective January 1, 2020, our three reportable segments are (1) Nurse and Allied Solutions; (2) Physician and Leadership Solutions; and (3) Technology and Workforce Solutions. The nurse and allied solutions segment includes our travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions businesses. The physician and leadership solutions segment includes our locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement businesses. The technology and workforce solutions segment includes remote video interpreting, vendor management systems, workforce optimization, recruitment process outsourcing, education, credentialing and flex pool management businesses.

#### **Non-GAAP Measures**

These slides contain certain non-GAAP financial information, which the Company provides as additional information, and not as an alternative, to the Company's condensed consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures include (1) adjusted EBITDA and (2) adjusted EBITDA margin. The Company provides such non-GAAP financial measures because management believes that they are useful both to management and investors as a supplement, and not as a substitute, when evaluating the Company's operating performance. Additionally, management believes that adjusted EBITDA and adjusted EBITDA margin serve as industry-wide financial measures. The non-GAAP measures provided in these slides are not in accordance with, or an alternative to, GAAP measures and may be different from non-GAAP measures, or may be calculated differently than other similarly titled non-GAAP measures, reported by other companies. They should not be used in isolation to evaluate the Company's performance. Further detail about the use and limitations of the non-GAAP measures found in these slides may be found in the footnotes provided herein or on the Company's website at http://amnhealthcare.investorroom.com/financialreports. Additionally, from time to time, additional information regarding non-GAAP financial measures, including pro forma measures, may be made available on the Company's website.

Presented below are the unaudited supplemental segment financial and operating data reflecting this realignment, including a Non-GAAP reconciliation table from net income to adjusted EBITDA, for the years ended December 31, 2019, 2018 and 2017.



	Year Ended December 31, 2019											
(dollars in thousands, except operating data)		First		Second		Third		Fourth		Total		
Revenue		-					_		_			
Nurse and allied solutions	\$	373,472	\$	367,994	\$	398,417	\$	422,705	\$ :	,562,588		
Physician and leadership solutions		137,077		142,449		143,842		139,394		562,762		
Technology and workforce solutions		21,892		24,734		25,338		24,793		96,757		
	\$	532,441	\$	535,177	\$	567,597	\$	586,892	\$2	2,222,107		
Segment operating income (1)	_		_						_			
Nurse and allied solutions	\$	53,556	\$	52,752	\$	52,533	\$	61,021	\$	219,862		
Physician and leadership solutions		15,872		18,861		17,547		19,098		71,378		
Technology and workforce solutions		10,383		11,336		11,426		10,754		43,899		
	\$	79,811	\$	82,949	\$	81,506	\$	90,873	\$	335,139		
Unallocated corporate overhead		13,834		16,217		12,255		15,434		57,740		
Adjusted EBITDA (2)	\$	65,977	\$	66,732	\$	69,251	\$	75,439	\$	277,399		
Adjusted EBITDA margin (3)		12.4%		12.5%		12.2%		12.9%		12.5%		
Gross Margin												
Nurse and allied solutions		28.5%		28.1%		28.5%		29.0%		28.5%		
Physician and leadership solutions		36.6%		37.2%		36.8%		37.2%		37.0%		
Technology and workforce solutions		92.6%		93.4%		93.0%		92.3%		92.8%		
Operating Data:												
Nurse and allied solutions												
Average healthcare professionals on assignment (4)		10,447		10,258		11,133		11,246		10,771		
Physician and leadership solutions												
Days filled (5)		40,496		41,563		42,700		40,149		164,908		
Revenue per day filled (6)	\$	1,988	\$	1,975	\$	1,971	\$	1,941	\$	1,969		



	Year Ended December 31, 2019											
(dollars in thousands)		First	Second		Third		Fourth			Total		
Reconciliation of Non-GAAP Items:												
Net income	\$	34,122	\$	28,869	\$	23,515	\$	27,482	\$	113,988		
Income tax expense		5,257		10,222		8,394		10,627		34,500		
Income before income taxes		39,379		39,091		31,909		38,109		148,488		
Interest expense, net, and other		5,673		6,065		7,830		8,859		28,427		
Income from operations		45,052		45,156		39,739		46,968		176,915		
Depreciation and amortization		11,710		12,718		17,085		17,007		58,520		
Share-based compensation (7)		5,186		3,702		2,825		4,528		16,241		
Acquisition, integration, and other costs (8)		4,029		5,156		9,602		6,936		25,723		
Adjusted EBITDA (2)	\$	65,977	\$	66,732	\$	69,251	\$	75,439	\$	277,399		



	Year Ended December 31, 2018											
(dollars in thousands, except operating data)		First		Second		Third	Fourth			Total		
Revenue	_						_					
Nurse and allied solutions	\$	346,542	\$	370,568	\$	346,268	\$	367,640	\$	1,431,018		
Physician and leadership solutions		154,589		165,145		158,087		139,667		617,488		
Technology and workforce solutions		21,358		22,395		22,487		21,328		87,568		
	\$	522,489	\$	558,108	\$	526,842	\$	528,635	\$2	2,136,074		
Segment operating income (1)		·			_	·	_					
Nurse and allied solutions	\$	53,231	\$	50,314	\$	47,703	\$	50,618	\$	201,866		
Physician and leadership solutions		19,743		25,232		23,003		18,099		86,077		
Technology and workforce solutions		8,640		10,337		11,461		10,935		41,373		
	\$	81,614	\$	85,883	\$	82,167	\$	79,652	\$	329,316		
Unallocated corporate overhead		15,095		15,823		14,739		13,281		58,938		
Adjusted EBITDA (2)	\$	66,519	\$	70,060	\$	67,428	\$	66,371	\$	270,378		
Adjusted EBITDA margin (3)		12.7%		12.6%		12.8%		12.6%		12.7%		
Gross Margin												
Nurse and allied solutions		28.2%		27.1%		28.0%		27.8%		27.7%		
Physician and leadership solutions		32.9%		36.4%		36.3%		36.4%		35.5%		
Technology and workforce solutions		90.5%		91.4%		91.9%		91.7%		91.4%		
Operating Data:												
Nurse and allied solutions												
Average healthcare professionals on assignment (4)		9,813		10,012		9,896		10,303		10,006		
Physician and leadership solutions												
Days filled (5)		52,794		55,225		50,069		41,000		199,089		
Revenue per day filled (6)	\$	1,953	\$	1,943	\$	2,019	\$	1,996	\$	1,976		



	Year Ended December 31, 2018											
(dollars in thousands)	First		Second		Third		Fourth		Total			
Reconciliation of Non-GAAP Items:												
Net income	\$ 42,681	\$	35,529	\$	27,918	\$	35,613	\$	141,741			
Income tax expense	7,185		12,910		10,068		14,781		44,944			
Income before income taxes	 49,866		48,439		37,986		50,394		186,685			
Interest expense, net, and other (9)	5,335		6,376		4,649		(217)		16,143			
Income from operations	 55,201		54,815		42,635		50,177		202,828			
Depreciation and amortization	7,886		10,606		11,296		11,449		41,237			
Share-based compensation (10)	2,864		3,281		1,809		2,861		10,815			
Acquisition, integration, and other costs (11)	568		1,358		(452)		1,884		3,358			
Legal settlement accrual increases (12)					12,140				12,140			
Adjusted EBITDA (2)	\$ 66,519	\$	70,060	\$	67,428	\$	66,371	\$	270,378			



	Year Ended December 31, 2017												
(dollars in thousands, except operating data)		First		Second		Third		Fourth		Total			
Revenue													
Nurse and allied solutions	\$	320,942	\$	308,306	\$	309,761	\$	329,107	\$	1,268,116			
Physician and leadership solutions		153,933		159,334		162,024		158,749		634,040			
Technology and workforce solutions		20,294		22,163		22,621		21,220		86,298			
	\$	495,169	\$	489,803	\$	494,406	\$	509,076	\$	1,988,454			
Segment operating income (1)	<del></del>												
Nurse and allied solutions	\$	47,891	\$	49,334	\$	41,325	\$	49,519	\$	188,069			
Physician and leadership solutions		22,629		23,018		23,681		21,717		91,045			
Technology and workforce solutions		7,536		9,911		10,129		8,678		36,254			
	\$	78,056	\$	82,263	\$	75,135	\$	79,914	\$	315,368			
Unallocated corporate overhead		14,891		15,080		13,438		15,545		58,954			
Adjusted EBITDA (2)	\$	63,165	\$	67,183	\$	61,697	\$	64,369	\$	256,414			
Adjusted EBITDA margin (3)		12.8%		13.7%		12.5%		12.6%		12.9%			
Gross Margin													
Nurse and allied solutions		28.0%		27.9%		27.3%		27.5%		27.7%			
Physician and leadership solutions		35.1%		34.1%		33.5%		32.9%		33.9%			
Technology and workforce solutions		89.2%		92.5%		91.7%		91.0%		91.2%			
Operating Data:													
Nurse and allied solutions													
Average healthcare professionals on assignment (4)		9,256		8,988		9,012		9,466		9,181			
Physician and leadership solutions													
Days filled (5)		55,243		58,660		58,881		56,591		229,375			
Revenue per day filled (6)	\$	1,862	\$	1,845	\$	1,892	\$	1,911	\$	1,877			



	Year Ended December 31, 2017											
(dollars in thousands)		First		Second		Third	Fourth			Total		
Reconciliation of Non-GAAP Items:												
Net income	\$	32,008	\$	31,255	\$	28,128	\$	41,167	\$	132,558		
Income tax expense		14,897		20,197		17,863		7,248		60,205		
Income before income taxes		46,905		51,452		45,991		48,415		192,763		
Interest expense, net, and other		5,130		4,928		4,837		4,782		19,677		
Income from operations		52,035		56,380		50,828		53,197		212,440		
Depreciation and amortization		7,668		7,959		8,132		8,520		32,279		
Share-based compensation		2,681		2,562		2,477		2,517		10,237		
Acquisition, integration, and other costs		781		282		260		135		1,458		
Adjusted EBITDA (2)	\$	63,165	\$	67,183	\$	61,697	\$	64,369	\$	256,414		



- (1) Segment operating income represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, unallocated corporate overhead, acquisition, integration, and other costs, and share-based compensation.
- (2) Adjusted EBITDA represents net income plus interest expense (net of interest income) and other, income tax expense, depreciation and amortization, acquisition, integration, and other costs, extraordinary legal expenses, legal settlement accrual increases and share-based compensation. Management believes that adjusted EBITDA provides an effective measure of the Company's results, as it excludes certain items that management believes are not indicative of the Company's operating performance and is a measure used in the Company's credit agreement and the indentures governing our 5.125% Senior Notes due 2024 and our 4.625% Senior Notes due 2027. Adjusted EBITDA is not intended to represent cash flows for the period, nor has it been presented as an alternative to income from operations or net income as an indicator of operating performance. Although management believes that some of the items excluded from adjusted EBITDA are not indicative of the Company's operating performance, these items do impact the statement of comprehensive income, and management therefore utilizes adjusted EBITDA as an operating performance measure in conjunction with GAAP measures such as net income.
- (3) Adjusted EBITDA margin represents adjusted EBITDA divided by revenue.
- (4) Average healthcare professionals on assignment represents the average number of nurse and allied healthcare professionals on assignment and revenue cycle solutions professionals contracted by the Company during the period presented. Excluding Advanced Medical, which was acquired during the second quarter of 2019, the average healthcare professionals on assignment was 10,098 for the twelve months ended December 31, 2019.
- (5) Days filled is calculated by dividing the locum tenens hours filled during the period by eight hours.
- (6) Revenue per day filled represents revenue of the Company's locum tenens business divided by days filled for the period presented.
- (7) Share-based compensation for the twelve months ended December 31, 2019 was impacted by two modifications during the first quarter and effective in 2019, a new vesting condition that resulted in accelerated expense recognition, and \$1,209,000 of additional expense related to the performance equity awards during the fourth quarter of 2019.
- (8) Acquisition, integration, and other costs for the twelve months ended December 31, 2019 include net increases in the fair value of contingent consideration liabilities for recently acquired companies of \$7,178,000 and extraordinary legal expenses of approximately \$7,100,000. Beginning in 2019, we exclude the impact of extraordinary legal expenses from the calculation of adjusted EBITDA because we believe that these expenses are not indicative of the Company's operating performance.



#### **Continued from page 8**

- (9) As a result of the adoption of a new accounting pronouncement on January 1, 2018, the Company now measures equity investments, except those accounted for using the equity method of accounting, at fair value with changes in fair value recognized through net income. Changes in fair value of equity investments recognized in interest expense, net, and other were \$1,359,000 and \$5,990,000 for the three months ended September 30, 2018 and December 31, 2018, respectively.
- (10) Share-based compensation for the three months ended September 30, 2018 was partially offset by a \$1,610,000 reduction related to performance equity awards.
- (11) Acquisition, integration, and other costs of \$874,000 for the three months ended September 30, 2018 were partially offset by a decrease in contingent consideration liabilities for recently acquired companies of \$1,326,000.
- (12) During the third quarter of 2018, the Company recorded increases to its legal accruals established in connection with settlement agreements entered into during September and October 2018 in two class actions related to wage and hour claims, both of which are considered probable. For the three months ended September 30, 2018, the increases amounted to \$12,140,000. Since the settlements are largely unrelated to the Company's operating performance, we excluded their impact in the calculation of adjusted EBITDA for the twelve months ended December 31, 2018. Amounts recorded in prior quarters in these two class actions and legal accruals related to other matters are immaterial and their impact was not excluded in the calculation of adjusted EBITDA in those prior quarters.

